THOUSAND OAKS, Calif.--(BUSINESS WIRE)--July 12, 2004--Amgen Inc.
(Nasdaq: AMGN), the world´s largest biotechnology company, today
announced the appointment of Brian Kotzin, M.D., to the position of
vice president and head of the Inflammation Therapeutic Area, one of
the company´s core research and development areas. Kotzin will direct
the global development efforts for all new Amgen product candidates in
the inflammation area. The company also announced the appointment of
Willard Dere, M.D., who formerly headed the Inflammation Therapeutic
Area, to the position of vice president and head of General Medicine,
a new emerging therapeutic focus area for Amgen.
"Brian is a highly respected clinical scientist with an
outstanding reputation in inflammation and immunology," said Beth
Seidenberg, M.D., Amgen´s senior vice president, Global Development
and chief medical officer. "I am confident that with his expertise and
leadership, Amgen will be well-positioned to continue building its
world-class inflammation franchise and developing a diverse portfolio
of products focused on improving patients´ lives."
Kotzin joins Amgen from the University of Colorado Health Sciences
Center in Denver, where he served as head of Clinical Immunology in
the Department of Medicine and as director of the Autoimmunity Center
of Excellence. He previously held the position of professor in the
Departments of Medicine, Pediatrics, and Immunology at the National
Jewish Medical and Research Center in Denver. In addition to previous
academic posts in rheumatology and microbiology/immunology, Kotzin
served at the Veterans Administration Medical Center in Denver as
chief of the Rheumatology Section. He received his medical degree from
Stanford and undergraduate degree in Mathematics from the University
of Southern California. He is board certified in rheumatology and
Kotzin has won numerous honors, including the Kirkland Scholar
Award for Lupus Research, the Henry Claman Chair in Clinical
Immunology, the Gretchen Kramer Award for Outstanding Contributions to
Medicine, and Chairmanship of the National Institutes of Health
Autoimmunity Centers of Excellence. Kotzin was recently appointed to
the Advisory Council of the National Institute of Arthritis and
Musculoskeletal and Skin Diseases at the National Institutes of
Health. He has published extensively and served on the editorial
boards of Arthritis and Rheumatism, The Journal of Immunology and the
Journal of Clinical Investigation.
Dere will now lead general medicine, a new therapeutic area for
Amgen consisting of bone, metabolism, nephrology, neurology,
cardiology and endocrinology. The creation of this new therapeutic
area demonstrates Amgen´s commitment to its growing portfolio of
general medicine products.
"We are pleased to recognize Will´s accomplishments with this
appointment," said Seidenberg. "Since joining Amgen in 2003, he has
made significant contributions to our product development organization
and he brings a tremendous amount of experience in general medicine to
this new key position."
Prior to joining Amgen and successfully leading the inflammation
therapeutic area, Dere was vice president of Endocrine, Bone and
General Medicine Research and Development at Eli Lilly and Company. He
previously was clinical associate professor at the Indiana University
School of Medicine and held hospital appointments at Wishard Memorial
Hospital and Richard Roudebush Veteran´s Administration Medical Center
in Indianapolis, Indiana. He also was an assistant professor at the
University of Utah School of Medicine and held hospital appointments
at the University of Utah Health Sciences Center and Veterans
Administration Medical Center in Salt Lake City, Utah.
Dere received his medical and undergraduate degrees from the
University of California at Davis.
Amgen is a global biotechnology company that discovers, develops,
manufactures and markets important human therapeutics based on
advances in cellular and molecular biology.
CONTACT: Amgen, Thousand Oaks
Mary Klem, 805-447-4587 (media)
Laura Biswas, 805-447-1060 (investors)
SOURCE: Amgen Inc.